Drug intelligence / Profile preview

Antidiazox

Development stage: Unknown
Lead developer: Global Napi Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Antidiazox is an antiprotozoal medication containing the active ingredient nitazoxanide. Developed and marketed by Global Napi Pharmaceuticals in Egypt, it is primarily indicated for the treatment of diarrhea caused by protozoan parasites, specifically *Giardia lamblia* and *Cryptosporidium parvum*. Nitazoxanide works by interfering with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in these parasites. It is available in both 500 mg tablet and 100 mg/5 ml powder for oral suspension formulations.

Brand names: Antidiazox
Other names: nitazoxanide

Targets

PFOR (Pyruvate:ferredoxin oxidoreductase)

Beyond the preview

Go deeper on Antidiazox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antidiazox.

Explore the full profile